The journal and the authors apologise for errors in the above article published in the May 2020 isuue (vol 182 Iss 5 pp 459–471) of the European Journal of Endocrinology. The legend to Figure 2 has an error describing the lower and upper limits calculated in the reference and dysmetabolic sub-cohorts. The correct legend is published below.
Figure 2 Steroid lower and upper limits per year of age in reference and dysmetabolic sub-cohorts. Green lines and dots: lower and upper limits calculated in the reference sub-cohorts. Black lines and white dots: lower and upper limits calculated in the dysmetabolic sub-cohorts. *P < 0.05.
Further a number of errors have been found in Table 3 and the correct table is published in full here.
Lower (LRL) and upper (URL) reference limits of age–dependent steroid hormones. Data are reported as the mean − 1.96 × s.d. and mean + 1.96 × s.d. of hormone distribution for LRL and URL, respectively, as calculated at every 5 years of adult age.
| Age (years) | ||||||||||
| 20 | 25 | 30 | 35 | 40 | 45 | 50 | 55 | 60 | 65 | |
| 17OHP5 | ||||||||||
| LRL | 5.1 (41–6.3) | 4.8 (3.9–5.8) | 4.4 (3.6–5.2) | 4.0 (3.4–4.6) | 3.6 (3.0–4.0) | 3.2 (2.7–3.4) | 2.8 (2.3–3.0) | 2.4 (1.8–2.7) | 2.1 (1.4–2.4) | 1.8 (1.1–2.2) |
| URL | 46.4 (35.1–68.6) | 42.4 (32.6–59.4) | 38.1 (30.0–50.1) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) | 33.5 (27.1–41.6) |
| DHEA | ||||||||||
| LRL | 9.9 (8.4–11.4) | 9.2 (8.3–10.2) | 8.4 (7.7–9.1) | 7.5 (6.8–8.1) | 6.5 (5.9–7.0) | 5.6 (5.0–6.1) | 4.7 (4.1–5.2) | 3.8 (3.3–4.3) | 3.1 (2.5–3.6) | 2.4 (1.9–3.0) |
| URL | 70.8 (58.9–87.4) | 64.0 (56.0–74.1) | 57.3 (51.6–64.1) | 50.4 (46.1–55.4) | 43.7 (40.3–47.8) | 37.2 (34.3–40.9) | 31.0 (28.5–34.5) | 25.5 (23.1–28.7) | 20.5 (18.3–23.5) | 16.2 (14.1–18.9) |
| 17OHP4 | ||||||||||
| LRL | 1.50 (1.13–1.71) | 1.46 (1.12–1.65) | 1.43 (1.11–1.60) | 1.40 (1.11–1.55) | 1.39 (1.12–1.52) | 1.38 (1.13–1.51) | 1.39 (1.15–1.54) | 1.41 (1.15–1.61) | 1.45 (1.15–1.74) | 1.50 (1.15–1.92) |
| URL | 7.36 (6.57–8.05) | 7.17 (6.45–7.77) | 6.95 (6.33–7.47) | 6.72 (6.16–7.17) | 6.47 (5.96–6.86) | 6.19 (5.73–6.61) | 5.90 (5.42–6.39) | 5.58 (5.05–6.21) | 5.23 (4.61–6.02) | 4.87 (4.11–5.84) |
| Cort. (B) | ||||||||||
| LRL | 3.5 (2.8–5.0) | 3.3 (2.8–4.7) | 3.1 (2.7–4.3) | 3.0 (2.6–4.0) | 2.8 (2.5–3.6) | 2.6 (2.4–3.4) | 2.4 (2.1–3.2) | 2.2 (1.8–3.2) | 2.0 (1.4–3.3) | 1.9 (1.1–3.4) |
| URL | 53.0 (46.0–77.3) | 50.9 (44.7–72.6) | 48.4 (43.1–67.3) | 45.4 (41.3–61.6) | 42.1 (39.0–55.3) | 38.6 (36.4–49.2) | 34.8 (33.4–43.9) | 30.9 (29.5–39.6) | 27.0 (25.0–36.4) | 23.1 (20.4–33.5) |
| 11S | ||||||||||
| LRL | 0.24 (0.19–0.31) | 0.24 (0.19–0.30) | 0.24 (0.20–0.29) | 0.24 (0.21–0.28) | 0.24 (0.21–0.28) | 0.25 (0.21–0.28) | 0.25 (0.21–0.28) | 0.25 (0.21–0.30) | 0.26 (0.20–0.32) | 0.26 (0.19–0.34) |
| URL | 3.65 (3.15–4.40) | 3.55 (3.12–4.21) | 3.45 (3.08–4.02) | 3.34 (3.02–3.83) | 3.23 (2.94–3.63) | 3.11 (2.83–3.49) | 2.99 (2.70–3.40) | 2.87 (2.55–3.34) | 2.74 (2.36–3.28) | 2.61 (2.17–3.24) |
| Cortisol | ||||||||||
| LRL | 152 (111–182) | 154 (119–180) | 156 (126–177) | 158 (134–176) | 160 (141–176) | 162 (144–177) | 165 (145–181) | 167 (143–186) | 169 (140–192) | 171 (137–198) |
| URL | 598 (564–645) | 584 (554–624) | 569 (544–603) | 555 (533–584) | 541 (521–566) | 527 (508–550) | 513 (494–538) | 499 (477–527) | 485 (459–516) | 471 (441–506) |
| A4 | ||||||||||
| LRL | 1.20 (1.08–1.30) | 1.15 (1.04–1.24) | 1.10 (1.00–1.18) | 1.06 (0.97–1.12) | 1.02 (0.94–1.08) | 0.99 (0.91–1.05) | 0.96 (0.89–1.03) | 0.94 (0.86–1.02) | 0.93 (0.83–1.02) | 0.92 (0.80–1.04) |
| URL | 5.13 (4.58–5.85) | 4.85 (4.39–5.45) | 4.57 (4.19–5.05) | 4.30 (3.99–4.67) | 4.02 (3.78–4.31) | 3.75 (3.55–3.97) | 3.48 (3.30–3.69) | 3.21 (3.00–3.47) | 2.95 (2.68–3.26) | 2.69 (2.37–3.07) |
A4, androstenedione; Cort. (B), cortisosterone; 11S, 11-deoxycortisol; 17OHP5, 17-hydroxypregnenolone; 17OHP4, 17-hydroxyprogesterone.
